Get the Stockscreener App
1.55
2.52%
-0.04
Chemomab Therapeutics Ltd Adr stock is traded at $1.55, with a volume of 24,865.
It is down -2.52% in the last 24 hours and up +0.00% over the past month.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
See More
Previous Close:
$1.59
Open:
$1.62
24h Volume:
24,865
Relative Volume:
0.32
Market Cap:
$11.15M
Revenue:
-
Net Income/Loss:
$-9.04M
P/E Ratio:
-1.0576
EPS:
-1.4656
Net Cash Flow:
$-23.55M
1W Performance:
-19.69%
1M Performance:
+0.00%
6M Performance:
-41.29%
1Y Performance:
+33.62%
1-Day Range:
$1.54
$1.62
1-Week Range:
$1.54
$1.93
52-Week Range:
$0.8288
$3.855
Chemomab Therapeutics Ltd Adr Stock (CMMB) Company Profile
Name
Chemomab Therapeutics Ltd Adr
Sector
Industry
Phone
972-77-331-0156
Address
KIRYAT ATIDIM, BUILDING 7, TEL AVIV
Compare CMMB vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMMB
Chemomab Therapeutics Ltd Adr
|
1.55 | 11.44M | 0 | -9.04M | -23.55M | -1.4656 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Chemomab Therapeutics Ltd Adr Stock (CMMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-13-24 | Initiated | Maxim Group | Buy |
| May-06-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Dec-19-23 | Resumed | ROTH MKM | Buy |
Chemomab Therapeutics Ltd Adr Stock (CMMB) Latest News
Chemomab Therapeutics (CMMB) flags going-concern risk and reliance on nebokitug - Stock Titan
Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewswire Inc.
Analysts Offer Insights on Healthcare Companies: ArriVent BioPharma, Inc. (AVBP), Chemomab Therapeutics (CMMB) and Reviva Pharmaceuticals Holdings (RVPH) - The Globe and Mail
Chemomab Therapeutics (CMMB) to Release Quarterly Earnings on Monday - Defense World
Pre Market Movers: DBVT, YCBD, KYTX Set The Pace - RTTNews
Chemomab Therapeutics (NASDAQ:CMMB) Shares Down 4.5% – Time to Sell? - Defense World
Chemomab’s nebokitug shows disease-modifying potential in PSC trial - Investing.com
Chemomab’s nebokitug shows disease-modifying potential in PSC trial By Investing.com - Investing.com UK
Chemomab Therapeutics (NASDAQ:CMMB) Cut to “Hold” at Zacks Research - Defense World
Chemomab reports positive 48-week data for PSC drug nebokitug - Investing.com
ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition - sharewise.com
Best Momentum Stocks to Buy for Oct. 23 - The Globe and Mail
New Strong Buy Stocks for Oct. 23: MQ, GES and More - Yahoo Finance
NVO's Rybelsus Gets FDA Nod to Reduce Heart Risk in Diabetes Patients - sharewise.com
SNY's Efdoralprin Alfa Meets Key Endpoints in Rare Disease Study - Yahoo Finance
Roche's Gazyva Secures FDA Nod for Label Expansion in Lupus Nephritis - sharewise.com
ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up - The Globe and Mail
NVO and LLY Stocks Slide as Trump Signals Price Cuts for GLP-1 Drugs - Yahoo Finance
Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in Japan - sharewise.com
RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy - sharewise.com
TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals - Zacks Investment Research
Zoetis Gains CVMP Backing for Lenivia, Eyes EU Approval in Dog OA Pain - sharewise.com
TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder - Yahoo Finance
Chemomab Therapeutics (NASDAQ:CMMB) Upgraded by Wall Street Zen to “Hold” Rating - Defense World
CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza - sharewise.com
OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data - sharewise.com
KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure - The Globe and Mail
AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study - Yahoo Finance
MRK Expands Tulisokibart Program in Three New Inflammatory Diseases - Nasdaq
Chemomab Therapeutics Ltd Share Price ADR Each Representing 80 Ord Shares SPON - Hargreaves Lansdown
Oppenheimer raises Chemomab stock price target to $25 on M&A potential - Investing.com
KURA Stock Rises More Than 15% This Past Week: Here's Why - Yahoo Finance
MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study - sharewise.com
NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study - Nasdaq
CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer - The Globe and Mail
TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate - Finviz
Aspire Biopharma (ASBP) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
Chemomab Therapeutics to Present at October 2024 Investor Conferences By Investing.com - Investing.com
Chemomab Therapeutics (CMMB) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Chemomab Therapeutics (CMMB) Stock Trends and Sentiment 2025 - MarketBeat
Chemomab Therapeutics (CMMB) Stock Forecast and Price Target 2026 - MarketBeat
Chemomab Therapeutics Ltd. Sponsored ADR Earnings and Revenue – NASDAQ:CMMB - TradingView — Track All Markets
symbol__ Stock Quote Price and Forecast - CNN
Chemomab (CMMB) Up on Fast Track Designation to CM-101 for PSC - Yahoo Finance
Chemomab Therapeutics LtdADR (CMMB) News, Articles, Events & Latest Updates - Stocktwits
What is the current Price Target and Forecast for Chemomab Therapeutics (CMMB) - Zacks Investment Research
Chemomab Therapeutics (CMMB) 10K Form and SEC Filings 2026 - MarketBeat
Chemomab Therapeutics (CMMB) Short Interest & Short Float | Updated Jan 2026 - MarketBeat
What date does Chemomab Therapeutics's (CMMB) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
What You Need To Know About Chemomab Therapeutics Ltd.'s (NASDAQ:CMMB) Investor Composition - Yahoo Finance
CHEMOMAB THERAPEUTICS LTD (CMMB) Stock Technical Analysis - Chartmill
Chemomab Therapeutics Ltd Adr Stock (CMMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):